Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
60
Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache. The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test.
CHU de Nice
Nice, CHUN, France
AP-HP Hôpital la Timone
Marseille, France
Evaluation of the atrioventricular block when verapamil is used in prevention of Cluster Headache.
Occurrence of the ratio of patients presenting a first degree atrioventricular block
Time frame: 27 months
Description of the different atrioventricular conduction abnormities and their incidence
Study of ECG results
Time frame: 27 months
Evaluation of the plasmatic concentration of verapamil and its metabolite (nor verapamil) in parallel with the occurrence of conduction abnormalities detected by electrocardiogram
Plasmatic concentration of verapamil and its metabolite (nor verapamil) dosed at each visit
Time frame: 27 months
Relation between pharmacokinetic/ pharmacodynamics of verapamil and the appearance of conduction abnormalities to determinate the maximal tolerated dose of verapamil.
The maximal tolerated dose of verapamil will be determined thanks to correlation between ECG results and Pharmacocinetics and pharmacodynamics
Time frame: 27 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.